Francesco Patti

Targets

• AQP4 1
• CD20 1

Filled chips are declared by the researcher; the others come from publications (number of works).

Now

Trials, publications and grants since Nov 2024.

• Publication

  How patients with neuromyelitis optica spectrum disease accumulate disability.

  Multiple sclerosis (Houndmills, Basingstoke, England), Oct 2026

• Publication

  Cognitive resilience and improvements in health-related quality of life over 4 years in people with relapsing multiple sclerosis treated with cladribine tablets: Results from the CLARIFY-MS Extension study.

  Multiple sclerosis and related disorders, Sept 2026

• Publication

  Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.

  Multiple sclerosis (Houndmills, Basingstoke, England), Aug 2026

• Publication

  Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

  Neurology and therapy, Aug 2026

• Publication

  Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

  Multiple sclerosis (Houndmills, Basingstoke, England), Jul 2026

• Publication

  A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England), Jun 2026

• Publication

  Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

  Neurology, May 2026

• Publication

  Threshold-Dependent Discordance Between STRATIFY JCV™ and IMMUNOWELL™ Assays in Relapsing Multiple Sclerosis.

  Neurology and therapy, Apr 2026

• Publication

  SPG4 and Dementia: Expanding the Clinical Spectrum.

  Annals of clinical and translational neurology, Mar 2026

• Publication

  Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

  Therapeutic advances in neurological disorders, Mar 2026

• Publication

  Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study.

  Neurology and therapy, Mar 2026

• Publication

  Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

  Neurology, Mar 2026

• Publication

  Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).

  Journal of neurology, Dec 2025

• Publication

  Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry.

  Therapeutic advances in neurological disorders, Dec 2025

• Publication

  Managing reactivation of multiple sclerosis during treatment with natalizumab.

  Multiple sclerosis (Houndmills, Basingstoke, England), Dec 2025

• Publication

  Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

  Neurology, Nov 2025

• Publication

  Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients.

  Therapeutic advances in neurological disorders, Nov 2025

Affiliations

• University of Catania

Co-authors

Who links you

Enter another researcher's profile link or ID to see who has published with both of you.